ArticleNature communications2026
Phase separation of ecDNA condensates establishes in-trans contact domains that boost selective MYC regulatory interactions.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phase separation of ecDNA condensates establishes in-trans contact domains that boost selective MYC regulatory interactions.Nature communications · 2026Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Extrachromosomal DNAs (ecDNAs) are circular DNA elements found in many human cancers, often carrying oncogenes and regulatory elements. In COLO320-DM colorectal cancer cells, MYC-harboring ecDNAs form nuclear clusters associated with oncogene overexpression, but the mechanisms underlying their aggregation and gene upregulation remain unclear. Here, we use a minimal polymer physics model to investigate the interactions between ecDNA BRD4 binding sites and BRD4 molecules at the single-molecule level. The model demonstrates that BRD4 induces phase separation of ecDNAs condensates, forming in-trans associated contact domains (I-TADs) enriched, beyond copy number, in regulatory contacts among specific ecDNA regions, particularly the PVT1-MYC fusions. This explains the preferential transcriptional upregulation of these fusions, while the canonical copy of MYC on the ecDNAs remains unaffected. The formation of I-TADs is validated against independent HiChIP and ChIA-PET data. Regulatory contacts are strongly enriched as soon as half a dozen ecDNAs cluster, then saturate because of steric hindrance, highlighting that even cells with few ecDNAs can experience pathogenic MYC upregulations. The BET inhibitor JQ1 reverses ecDNA phase separation, abolishing I-TADs and reducing MYC transcription in a switch-like manner, as confirmed by RT-qPCR experiments. These findings clarify the role of ecDNA condensates in gene regulation and highlight potential therapeutic strategies targeting BRD4-mediated interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.